Expansion Investment GRAM is executing a growth push with a $100 million investment into a new fifth sterile-filling line and GMP facility, signaling capacity expansion and readiness to take on larger or more complex sterile injectable programs.

Strategic Partnerships The company emphasizes collaboration with drug delivery device innovators (notably SHL Medical), presenting opportunities to co-develop autoinjector and on-body delivery solutions that align with client needs and speed to market.

Leadership Momentum A recent CEO appointment and promotion to chief executive indicates strategic leadership continuity and growth-driven vision, which can reassure potential clients and partners about long-term capacity and strategic planning.

Quality and Compliance GRAM’s GMP-focused investments and track record in sterile fill-finish for vials, syringes, and cartridges position it as a reliable CDMO for programs requiring stringent quality, regulatory compliance, and scalable manufacturing.

Recognition and Value Awards for growth and Best and Brightest Places to Work signal a strong employer brand and operational excellence, which can translate into dependable project execution and talent resources for client programs.